ChromaDex (CDXC) News Today → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free CDXC Stock Alerts $3.83 +0.08 (+2.13%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineChromaDex GAAP EPS of -$0.01 in-line, revenue of $22.2M misses by $1.41Mmsn.com - May 8 at 5:13 PMChromaDex Corporation Reports First Quarter 2024 Financial Resultsfinance.yahoo.com - May 8 at 5:13 PMChromaDex is about to announce its earnings — here's what to expectmarkets.businessinsider.com - May 7 at 6:39 PMAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% Undervaluedfinance.yahoo.com - May 6 at 8:53 AMChromaDex Co. (NASDAQ:CDXC) Short Interest Updatemarketbeat.com - May 1 at 10:30 PMChromaDex Corporation (CDXC)finance.yahoo.com - May 1 at 8:58 PMChromaDex (CDXC) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - May 1 at 8:23 AMChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplementfinance.yahoo.com - April 30 at 2:38 PMChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplementbusinesswire.com - April 30 at 8:32 AMChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®businesswire.com - April 25 at 8:34 AMChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024businesswire.com - April 24 at 8:34 AMChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Marketbusinesswire.com - April 23 at 8:32 AMChromaDex (CDXC) Price Target Increased by 9.92% to 6.60msn.com - April 17 at 9:01 PMShort Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 12.8%marketbeat.com - April 14 at 11:34 PMChromaDex (NASDAQ:CDXC) PT Raised to $6.00marketbeat.com - April 9 at 10:13 AM3 Chemical Stocks Poised for Gainsstocknews.com - March 27 at 5:01 PMChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Programbusinesswire.com - March 26 at 8:32 AMShort Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%marketbeat.com - March 19 at 3:32 PMEquities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC)marketbeat.com - March 14 at 7:36 AMChromaDex Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 8 at 8:50 AMChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC)marketbeat.com - March 8 at 7:22 AMPersona 3 Reload is getting the DLC it needs, but not the one it deservesuk.sports.yahoo.com - March 8 at 1:24 AMChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 3:23 PMChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAfinance.yahoo.com - March 7 at 3:23 PMWhat Wall Street expects from ChromaDex's earningsmarkets.businessinsider.com - March 6 at 11:44 PMCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023investorplace.com - March 6 at 11:01 PMEarnings Preview For ChromaDexbenzinga.com - March 6 at 6:44 PMChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Resultsfinance.yahoo.com - March 6 at 6:44 PMInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the companyfinance.yahoo.com - March 2 at 12:51 PMChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024finance.yahoo.com - February 21 at 12:29 PMChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024businesswire.com - February 21 at 8:32 AMTop 3 Accelerating Chemical Stocks to Considerentrepreneur.com - February 6 at 10:27 AMChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024finance.yahoo.com - February 5 at 1:35 PMChromaDex to Present at the Lytham Partners 2024 Investor Select Conferencefinance.yahoo.com - January 26 at 6:46 PMChromaDex: Growth At A Reasonable Priceseekingalpha.com - January 24 at 4:54 PMChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profitfinance.yahoo.com - January 19 at 9:29 AMChromaDex (NASDAQ:CDXC) Upgraded at StockNews.commarketbeat.com - December 29 at 1:06 AMChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru Niagenbusinesswire.com - December 20 at 3:28 PMChromaDex Flat on Assistance to Militarybaystreet.ca - December 20 at 10:28 AMChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®finance.yahoo.com - December 20 at 10:28 AMA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)finance.yahoo.com - November 30 at 3:43 PMAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervaluedfinance.yahoo.com - November 28 at 10:24 AMNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor ...businesswire.com - November 15 at 12:47 PMNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patientsfinance.yahoo.com - November 15 at 12:47 PMChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 4:40 PMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Chromadex (CDXC) and Glaukos (GKOS)markets.businessinsider.com - November 10 at 6:38 AMChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023finance.yahoo.com - November 9 at 12:39 PMChromaDex GAAP EPS of -$0.01 beats by $0.02, revenue of $19.49M misses by $0.88Mmsn.com - November 8 at 9:06 PMChromaDex: Q3 Earnings Insightsbenzinga.com - November 8 at 9:06 PMChromaDex Corporation Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 8 at 9:06 PM Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address “Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. CDXC Media Mentions By Week CDXC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDXC News Sentiment▼0.690.37▲Average Medical News Sentiment CDXC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDXC Articles This Week▼41▲CDXC Articles Average Week Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MDWD News Today FTLF News Today BTMD News Today NAII News Today ACB News Today MTEX News Today MNMD News Today USNA News Today INO News Today GLUE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDXC) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.